Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection

被引:0
|
作者
Katherine A. Lyseng-Williamson
Lesley J. Scott
机构
[1] Adis,
来源
关键词
Efavirenz; Tenofovir Disoproxil Fumarate; Virological Failure; Emtricitabine; Etravirine;
D O I
暂无
中图分类号
学科分类号
摘要
The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Eviplera™ [EU]; Complera™ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient population, rilpivirine plus emtricitabine/tenofovir disoproxil fumarate was noninferior to efavirenz plus emtricitabine/tenofovir disoproxil fumarate in terms of reducing viral HIV-1 RNA level to <50 copies/mL and was generally better tolerated than efavirenz plus emtricitabine/tenofovir disoproxil fumarate.
引用
收藏
页码:715 / 722
页数:7
相关论文
共 50 条